Key result
Elevated serum Lp-PLA2 is linked to increased cardiovascular risk in coronary and carotid disease.
Answers are grounded in this paper and cite their sources.
Epps KC, Wilensky RL (Hospital of the University of Pennsylvania and Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA). Lp-PLA2– a novel risk factor for high-risk coronary and carotid artery disease. (Review) J Intern Med2010; 269: 94–106. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is at the crossroads of lipid metabolism and the inflammatory response. It is produced by inflammatory cells, bound to LDL and other lipoproteins, and once in the arterial wall facilitates hydrolysis of phospholipids. Elevated serum levels of Lp-PLA2 have been associated with increased cardiovascular risk in healthy populations and in patients with known vascular disease. Here, we review the role of Lp-PLA2 in the development of atherosclerosis and progression to unstable disease, the utility of Lp-PLA2 as a risk predictor for coronary and carotid events and the potential clinical benefit of pharmacologic inhibition of Lp-PLA2.
No takes yet. Share an insight, caveat, or question.
Epps et al. (2010) conducted a review in High-risk coronary and carotid artery disease. Lipoprotein-associated phospholipase A2 (Lp-PLA2) was evaluated on Coronary and carotid events. Elevated serum Lp-PLA2 is associated with increased cardiovascular risk and serves as a risk predictor and potential therapeutic target in coronary and carotid artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: